65,370 Shares in Elanco Animal Health Incorporated $ELAN Bought by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, HoldingsChannel reports. The fund bought 65,370 shares of the company’s stock, valued at approximately $1,479,000.

A number of other institutional investors also recently bought and sold shares of ELAN. UBS Group AG raised its holdings in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the period. Artemis Investment Management LLP bought a new stake in Elanco Animal Health during the fourth quarter valued at about $55,693,000. Goldman Sachs Group Inc. raised its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Bowen Hanes & Co. Inc. bought a new stake in Elanco Animal Health during the third quarter valued at about $47,626,000. Finally, Dimensional Fund Advisors LP raised its holdings in Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after acquiring an additional 1,962,276 shares during the period. 97.48% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $23.71 on Thursday. Elanco Animal Health Incorporated has a 52 week low of $12.97 and a 52 week high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The business’s 50-day simple moving average is $23.00 and its two-hundred day simple moving average is $23.30. The stock has a market cap of $11.84 billion, a PE ratio of -47.41, a P/E/G ratio of 2.46 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the previous year, the firm posted $0.37 earnings per share. The business’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of recent analyst reports. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Leerink Partners raised their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.